Close
CDMO Safety Testing 2026
Novotech

BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update At BIO CEO & Investor Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing...
- Advertisement -

BioSante Pharmaceuticals, Inc. will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14-15, 2011 at the Waldorf-Astoria in New York. Stephen M. Simes, BioSante’s president & CEO, will speak today, Monday February 14, 2011 at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel® (testosterone gel) Phase III clinical development program including safety data. A live audio webcast of Mr. Simes’ remarks may be accessed at: http://www.veracast.com/webcasts/bio/ceoinvestor2011/16113289.cfm.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In...

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

The Pfizer Innovent Cancer Deal has been finalized, establishing...

The Push for Greater Accuracy in Clinical Trials

Clinical trials are the foundation of modern medicine. Every...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »